BTIG analyst Marvin Fong maintained a Buy rating on Mercadolibre (MELI – Research Report) today and set a price target of $2,500.00. The ...

In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price ...

Investing.com -- BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025. The brokerage ...

Marine Systems, a key segment for GD, continues to face margin pressure despite robust sales growth, as supply chain ...

Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.

Insulet (NASDAQ:PODD – Get Free Report) had its price target hoisted by equities research analysts at Stifel Nicolaus from $245.00 to $293.00 in a research note issued on Friday,Benzinga reports. The ...

On Monday, BTIG analyst Andrew Harte maintained a Neutral rating on Global Payments Inc. (NYSE:GPN) stock, despite an approximate 11% increase in share value since the company's third-quarter 2024 ...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...

On Tuesday, BTIG analyst Thomas Catherwood maintained a Neutral rating on shares of Kilroy Realty Corporation (NYSE:KRC), following the company's release of its fourth-quarter 2024 financial results.

Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, ...

HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $5.75 ...